View Post

Drug to Replace Chemotherapy May Reshape Cancer Care

In In The News by Barbara Jacoby

By: Kanoko Matsuyama From: bloomberg.com * Promising treatment may reach far more breast cancer patients * Daiichi drug may outsell Roche’s Herceptin, spark dealmaking A class of drugs is emerging that can attack cancer cells in the body without damaging surrounding healthy ones. They have the potential to replace chemotherapy and its disruptive side effects, reshaping the future of cancer …

View Post

Evaluating Use of Bone-Modifying Agents to Treat Skeletal-Related Events in Cancer

In In The News by Barbara Jacoby

By: Laura Joszt From: ajmc.com Skeletal-related events are frequent complications in patients with cancers. Two abstracts analyzed the use of bone-modifying agents in patients with newly diagnosed multiple myeloma and breast cancer. Skeletal-related events are frequent complications in patients with cancers. Two abstracts presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting analyzed the use of bone-modifying …

View Post

From Prevention to Palliative Care: Optimizing the Breast Cancer Patient Experience With Nurse Navigation

In In The News by Barbara Jacoby

By: Darcy Burbage, MSN, RN, AOCN, CBCN From: oncologynurseadvisor.com Breast cancer is the most commonly diagnosed cancer in women, with incidence rates of invasive cancer upwards of 200,000 new cases per year plus an estimated additional 63,000 cases of in situ breast cancer.1 Because of this, more than 3.5 million breast cancer survivors are alive today either with a history …

View Post

Jefferson researcher discovers a population of bone cells that subdues cancer

In In The News by Barbara Jacoby

Source: jefferson.edu From: news-medical.net In breast cancer, there are cases of women and men whose cancer returns in their bones 20-30 years after they were treated for their primary disease and thought they were cancer-free. This phenomenon always puzzled Jefferson researcher Karen Bussard, PhD. How is it possible that breast cancer cells from a primary tumor are able to reach …

View Post

6 months treatment with Herceptin is as good as 12 months for preventing breast cancer return

In Clinical Trials by Barbara Jacoby

By: Peter Thorley, University of Warwick From: medicalxpress.com A new study co-led by the University of Warwick Clinical Trials Unit has shown that shortening the duration of a therapy for breast cancer patients does not increase the risk of their cancer returning. The majority of clinical trials in cancer assess either new treatments or additional treatments to the current standard …

View Post

Breast Cancer Recurrence Not Linked To Anesthesia Administration Mode

In In The News by Barbara Jacoby

By: Jenna Bassett, PhD From: clinicaloncology.com “The leading cause of death after cancer surgery is the recurrence of cancer,” said senior study author Jin-Tae Kim, MD, PhD, of the Department of Anesthesiology and Pain Medicine at Seoul National University Hospital, South Korea. “If there is a difference in cancer recurrence rate according to the type of anesthesia used, even a …

View Post

ASCO 2019: Test All Triple Negative Breast Cancer Patients for PD-L1

In Clinical Trials by Barbara Jacoby

From: physiciansweekly.com Latest analysis from IMpassion trial confirms need for testing One of the repeated themes of the American Society of Clinical Oncology meeting here was the need for baseline testing of any target that can inform truly precision use of targeted therapies, and that message came through loud and clear during an oral abstract session devoted to treatment of …

View Post

FDA Approvals in Non-Hodgkin Lymphoma, Breast Cancer, GVHD, and Mesothelioma

In In The News by Barbara Jacoby

By: Kristi Rosa From: onclive.com FDA approvals in non-Hodgkin lymphoma, breast cancer, graft-versus-host disease, and mesothelioma, and a breakthrough therapy designation in cervical cancer. The FDA has approved the R2 regimen of lenalidomide plus rituximab for use in patients with previously treated follicular lymphoma and marginal zone lymphoma. The approval was primarily based on findings from the phase III AUGMENT …

View Post

Breast MRI may be too sensitive for some for annual cancer screening

In In The News by Barbara Jacoby

By: Amy Norton, HealthDay News From: upi.com Researchers say that while MRI picks up more than a mammogram, it also can lead to false positives and unneeded biopsies. Breast MRI screening is a good way to detect small tumors, but it’s unclear how much it benefits women with a history of breast cancer, a new study finds. Right now, experts …